Browsing by Author Patnaik, Amita

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 15 of 15
Issue DateTitleAuthor(s)Citation
2014Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trialKefford, Richard (Rick); Boasberg, Peter; Chmielowski, Bartosz; Daud, Adil; Dronca, Roxana; Ebbinghaus, Scot; Elassaiss-Schaap, Jeroen; Gangadhar, Tara C.; Gergich, Kevin; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Iannone, Robert; Joseph, Richard W.; Joshua, Anthony M.; Kang, Peter; Li, Xiaoyun; Mateus, Christine; Patnaik, Amita; Postow, Michael; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Western Clinical School: Westmead Millennium InstituteAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, 9948, 2014,pp 1109-1117
2016Association of pembrolizumab with tumor response and survival among patients with advanced melanomaHersey, Peter; Daud, Adil; et al, Various; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joshua, Anthony M.; Kefford, Richard F; Patnaik, Amita; Ribas, Antoni; Wolchok, Jedd D.; Northern Clinical School: SurgeryAssociation of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA: The Journal of the American Medical Association, vol.315, 15, 2016,pp 1600-1609
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2016Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with PembrolizumabHersey, Peter; Daud, Adil; et al, Various; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Kefford, Richard F.; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Northern Clinical School: SurgeryEvaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab, Journal of Clinical Oncology, vol.34, 13, 2016,pp 1510-1517
2017Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trialHui, Rina; Ahn, Myung-Ju; Eder, Joseph; et al, Various; Gandhi, L; Garon, Edward; Goldman, J W; Hellmann, M D; Horn, L; Leighl, Natasha; Patnaik, Amita; Western Clinical School: Medicine (Westmead)Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trial, Annals of Oncology, vol.28, 4, 2017,pp 874-881
2015Pembrolizumab for the Treatment of Non-Small-Cell Lung CancerHui, Rina; Aggarwal, Charu; Balmanoukian, Ani; Carcereny, Enric; Eder, Joseph; et al, Various; Garon, Edward; Gubens, Matthew; Horn, Leora; Leighl, Natasha; Patnaik, Amita; Rizvi, Naiyer; Western Clinical School: Medicine (Westmead)Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, The New England Journal of Medicine, vol.372, 71, 2015,pp 2018-2028